Recruiting

Noom's Programs

Sponsor:

Noom Inc.

Code:

NCT07588984

Conditions

Obesity & Overweight

Weight Loss

Preventative Health

Body Weight

Cardiovascular Disease Risk Factor

Eligibility Criteria

Sex: All

Age: 18 - 64

Healthy Volunteers: Not accepted

Interventions

Noom Weight

Free Tier

Education-only control

Semaglutide

Tirzepatide

Study Details

Brief summary:

This research program includes two coordinated prospective studies (FLOURISH and THRIVE) evaluating the real-world effectiveness of Noom's digital health programs on weight, cardiometabolic biomarkers, physiological health indicators, and program engagement.

FLOURISH is a 6-arm prospective cohort study comparing an Education-only control, Noom Weight, standard-dose compounded semaglutide, microdose compounded semaglutide, standard-dose tirzepatide (Noom Plus), and microdose tirzepatide (Noom Plus Microdose).

THRIVE is a nested 2-arm prospective study comparing a Proactive Health program to a Noom Free Tier control.

Participants complete monthly surveys, remote biomarker collection (Tasso device), connected-scale weigh-ins, and in-app biometric assessments (FaceScan, BodyScan). Microdose and Free Tier arms also use wearable fitness trackers. Primary outcomes are changes in cardiometabolic biomarkers, weight, body composition, and GLP-1 side effect profile. Total N = 2,310; 24-month duration.

Conditions

Obesity & Overweight

Weight Loss

Preventative Health

Body Weight

Cardiovascular Disease Risk Factor

Study ID

NCT07588984

Start date

May 26, 2026

Status verified date

May, 2026

Completion date

May, 2029

Anticipated

Primary completion date

May, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 64

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Speaks English
  • Community-dwelling, community-living status
  • Able to ambulate independently, with or without aids or devices
  • Unless medically indicated, willingness to stay on current program for 12 months and participate in all study activities
  • Provides informed consent for study participation
  • Commitment and willingness to participate, as assessed by completion of decisional balance exercise
  • Program-specific eligibility:
  • Medication arms only: Meets standard of care program enrollment criteria for GLP-1 medication. Did not add other products or programs to Noom subscription.
  • Noom Weight only: Individual who is not interested in medication
  • Education-only Control Group: Individual who is interested in weight loss who is not currently enrolled in a structured weight loss program or medication program and does not intend to for the duration of the study Free Tier only: Willingness to use Free Tier
  • BMI greater than or equal to 25.0 for all FLOURISH arms

Exclusion Criteria:

  • Study screener completed more than 11 days after Noom program enrollment if participating in a Noom program (GLP-1 programs, Noom Weight, and Free Tier)
  • GLP-1 use in the last 24 weeks (prior to Noom program enrollment if in GLP-1 arm)
  • Female who is pregnant, breast-feeding, or intends to become pregnant during the 12-month program
  • Previous or planned (during the 12-month study) bariatric surgery
  • Active eating disorder
  • Active cancer
  • Type 1 diabetes or current Insulin use
  • Currently taking a medication known to cause weight gain (e.g., antipsychotics, antidepressants, diabetes medication, or corticosteroids)
  • Depression screen results in a PHQ-8 score of 20 or greater.

All medicated arms and Noom Weight arms (only):

\- Purchased more than the base Noom program offered for participant's specific arm

GLP-1 Medication Arms Only:

  • GLP-1 agonist use is contraindicated (per program criteria) in members with:
  • Personal or family history of medullary thyroid cancer
  • Personal or family history of Multiple Endocrine Neoplasia Type 2 (MEN2)
  • Personal history of Pancreatitis

Study Design

Enrollment

2541 participants

Anticipated

Interventions and Outcome Measures

Arms

Education only (control)

Arm 1 of FLOURISH: This is an active control condition in which participants will receive weekly informational newsletters for 12 months. This group will not have access to the Noom app (except for research purposes) and will not receive GLP-1 medications.

Noom Weight

Arm 2 of FLOURISH: Noom Weight users will have access to all in-app features. This group will not receive GLP-1 medications. Followed for 12 months.

Standard GLP-1Rx

Arm 3 of FLOURISH: Standard GLP-1 users will follow a protocol for Noom's standard dose of compounded semaglutide and will have access to all in-app features. Followed for up to 12 months of program with 18 and 24 month follow-up post-GLP-1 discontinuation.

Microdose GLP-1Rx

Arm 4 of FLOURISH: Microdose GLP-1 users will follow a microdose protocol of compounded semaglutide and will have access to all in-app features. Followed for up to 12 months of program with 18 and 24 month follow-up post-GLP-1 discontinuation.

Noom Plus

Arm 5 of FLOURISH: Participants will follow a protocol for Noom's standard dose of compounded tirzepatide and will have access to all in-app features. Followed for up to 12 months of program with 18 and 24 month follow-up post-GLP-1 discontinuation.

Noom Plus Microdose

Arm 6 of FLOURISH: Noom Plus Microdose users will follow a microdose protocol for compounded tirzepatide and will have access to all in-app features. Followed for up to 12 months of program with 18 and 24 month follow-up post-GLP-1 discontinuation.

Noom Free Tier (control)

Arm 1 of THRIVE: This is an active control condition in which users enrolled in Noom's Free Tier program will have access to app features available to Free Tier. This group will not receive GLP-1 medications. Followed for 12 months.

Proactive Health

Arm 2 of THRIVE: Proactive health users will follow the microdose protocol for compounded semaglutide indicated for preventive health/longevity. They will have access to all in-app features. Followed for 12 months.

Interventions

Noom Weight

App-based behavioral weight management program providing structured educational content, coaching, and self-monitoring tools focused on nutrition, physical activity, and habit formation.

Free Tier

Basic free-to-use tier of the Noom app with limited features; no structured behavioral program or medication.

Education-only control

Weekly informational newsletters based on the CDC curriculum for 12 months; no structured behavioral program or medication.

Semaglutide

Standard clinical dosing of compounded semaglutide as part of Noom Med GLP-1Rx program per clinical standard of care, combined with behavioral coaching via the Noom app.

Tirzepatide

Standard clinical dosing of tirzepatide as part of Noom Plus program per clinical standard of care, combined with enhanced behavioral coaching.

Microdose semaglutide

Below-standard clinical dosing (microdose) of compounded semaglutide as part of Noom Med GLP-1Rx Microdose program, combined with behavioral coaching via the Noom app.

Microdose tirzepatide

Below-standard clinical dosing (microdose) of tirzepatide as part of Noom Plus Microdose program, combined with enhanced behavioral coaching.

Primary outcome measure

  • Change in Body Weight [ Time Frame: Monthly, Baseline through Month 12 (and Months 18 & 24 for FLOURISH GLP-1 arms) ]
  • Change in fasting glucose [ Time Frame: Baseline, Month 2, Month 4, Month 8, Month 12 ]
  • Change in HbA1c [ Time Frame: Baseline, Month 2, Month 4, Month 8, Month 12 ]
  • Change in LDL cholesterol [ Time Frame: Baseline, Month 2, Month 4, Month 8, Month 12 ]
  • Change in HDL cholesterol [ Time Frame: Baseline, Month 2, Month 4, Month 8, Month 12 ]
  • Change in total cholesterol [ Time Frame: Baseline, Month 2, Month 4, Month 8, Month 12 ]
  • Change in triglycerides [ Time Frame: Baseline, Month 2, Month 4, Month 8, Month 12 ]
  • Change in Body Composition [ Time Frame: Monthly, Baseline through Month 12 ((and Months 18 & 24 for FLOURISH GLP-1 arms) ]
  • GLP-1 Side Effect Profile [ Time Frame: Baseline (pre-treatment), Monthly through Month 12 ]

Central Contacts and Locations

Central contacts

Locations

Noom, Inc.

Recruiting

Princeton, New Jersey, United States, 08542

Contacts

More Information

Sponsor

Noom Inc.

Last update posted

Nov 16, 2026

Last verified

May, 2026

Keywords

  • GLP-1
  • Microdose
  • weight
  • body composition
  • metabolic
  • biomarkers
  • longevity
  • glucagon-like peptide-1
  • semaglutide
  • tirzepatide
  • microdosing
  • digital health
  • weight loss
  • behavioral health
  • real world evidence

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-17. This information was provided to ClinicalTrials.gov by Noom Inc. on 2026-11-16. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.